CA - Mind Medicine a new outperform at Baird on LSD-based asset for anxiety
2024-05-29 09:29:04 ET
More on Mind Medicine
- MindMed releases promising phase 2 data on LSD-related anxiety therapy
- MindMed: Breakthrough Status From The FDA For LSD Therapy
- Psychedelics Closer To Commercialization; Compass Far And Away The Leader
- Mind Medicine GAAP EPS of -$1.14 misses by $0.60
- Mind Medicine (MindMed) Inc. (MNMD) Q1 2024 Earnings Call Transcript